Cargando…
In vitro models for head and neck cancer: Current status and future perspective
The 5-year overall survival rate remains approximately 50% for head and neck (H&N) cancer patients, even though new cancer drugs have been approved for clinical use since 2016. Cancer drug studies are now moving toward the use of three-dimensional culture models for better emulating the unique t...
Autores principales: | Moya-Garcia, Christian R., Okuyama, Hideaki, Sadeghi, Nader, Li, Jianyu, Tabrizian, Maryam, Li-Jessen, Nicole Y. K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381731/ https://www.ncbi.nlm.nih.gov/pubmed/35992863 http://dx.doi.org/10.3389/fonc.2022.960340 |
Ejemplares similares
-
Current Status and Future Perspectives on the Etiology of Esophageal Adenocarcinoma
por: Thrift, Aaron P., et al.
Publicado: (2012) -
MR-Guided Radiotherapy for Head and Neck Cancer: Current Developments, Perspectives, and Challenges
por: Boeke, Simon, et al.
Publicado: (2021) -
Chitosomes Loaded with Docetaxel as a Promising Drug Delivery System to Laryngeal Cancer Cells: An In Vitro Cytotoxic Study
por: Moya-Garcia, Christian R., et al.
Publicado: (2023) -
Biotherapeutic Antibodies for the Treatment of Head and Neck Cancer: Current Approaches and Future Considerations of Photothermal Therapies
por: Al Qaraghuli, Mohammed M.
Publicado: (2020) -
Artificial Intelligence for Personalized Medicine in Thyroid Cancer: Current Status and Future Perspectives
por: Li, Ling-Rui, et al.
Publicado: (2021)